Also from this source

You just read:

Transcept Pharmaceuticals Initiates Phase 2 Study of TO-2061 in Obsessive Compulsive Disorder Patients Who Do Not Respond Adequately to Approved First Line Pharmacotherapy

News provided by

Transcept Pharmaceuticals, Inc.

Mar 14, 2011, 07:35 ET